Evidence map›Paper›PMID 29439458›Full record

ArticleMaterials (Basel, Switzerland)2018

Carrier-Free Microspheres of an Anti-Cancer Drug Synthesized via a Sodium Catalyst for Controlled-Release Drug Delivery.

Yong Xie, Xinxin Ma, Xujie Liu, Qingming Long, Yu Wang, Youwei Yao, Qiang Cai

Abstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yong XieGraduate School at Shenzhen, Tsinghua University, Shenzhen 518055, China. jy15@mails.tsinghua.edu.cn.
Xinxin MaSouthern China Branch, Sinopec Commercial Holding Company Limited, Guangzhou 510630, China. 15201106417@163.com.
Xujie LiuGraduate School at Shenzhen, Tsinghua University, Shenzhen 518055, China. liu.xujie@sz.tsinghua.edu.cn.ORCID 0000-0001-8713-4287
Qingming LongGraduate School at Shenzhen, Tsinghua University, Shenzhen 518055, China. 13303275396@163.com.
Yu WangState Key Laboratory of New Ceramics and Fine Processing, School of Materials Science and Engineering, Tsinghua University, Beijing 100084, China. zpheadwang@163.com.
Youwei YaoGraduate School at Shenzhen, Tsinghua University, Shenzhen 518055, China. yaoyw@sz.tsinghua.edu.cn.
Qiang CaiGraduate School at Shenzhen, Tsinghua University, Shenzhen 518055, China. caiqiang@tsinghua.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are several challenges involved in the development of effective anti-cancer drugs, including accurate drug delivery without toxic side effects. Possible systemic toxicity and the rapid biodegradation of drug carriers are potential risks in the use of carriers for drug-delivery formulations. Therefore, the carrier-free drug delivery of an anti-cancer drug is desirable. Herein, 4-amino-2-benzyl-6-methylpyrimidine (ABMP) was synthesized via a new method using a sodium catalyst, and proved to be effective in inducing breast cancer cell (MDA-MB-231) apoptosis. Moreover, the transparent amorphous state solid of ABMP was demonstrated to have a slow-release property in phosphate buffer solution (PBS). Microspheres of ABMP were prepared with diameters in the range of 5-15 μm. The slow-release property of the ABMP microspheres indicated their potential use for controlled-release drug delivery. We believe that microspheres of ABMP have potential as a new kind of carrier-free anti-cancer drug delivery system.

Indexed as

4-amino-2-benzyl-6-methylpyrimidinebiomaterialcarrier-freedrug delivery

Identifiers

PMID29439458
PMCPMC5848978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.